euro adhoc: Intercell AG / Restructuring & Recapitalisations / Intercell management board resolves EUR 150 million capital increase - HSR waiting period for the strategic partnership with Novartis has

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

30.08.2007

Vienna (Austria), August 30, 2007 - The management board of Intercell
AG today resolved, subject to the approval of the supervisory board,
to issue 4.8 million new shares of common stock to its strategic
partner Novartis at an issue price of EUR 31.25 per share. The
subscription rights of existing shareholders will be excluded. The
report on the exclusion of the statutory subscription rights will be
published tomorrow in the Wiener Zeitung and on www.intercell.com.

Within the scope of a strategic alliance agreement concluded in early
July 2007, Novartis has committed to subscribe for the newly issued
shares, resulting in an investment of EUR 150 million into Intercell.
One of the conditions to closing the strategic partnership was
clearance under U.S. antitrust law. Today's resolution to make the
capital increase effective follows the expiration of the waiting
period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976,
as amended (the "HSR Act"), whereby the strategic partnership can
proceed under U.S. antitrust law. The waiting period expired in the
ordinary course under the HSR Act 30 days after the initial filing.
Completion of the capital increase and start of trading of the new
shares on the Vienna Stock Exchange is expected for mid/end September
2007.

This document is not for release, publication or distribution in the
United States of America.

This release does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities in the United States
of America, Austria, Germany or any other jurisdiction. The
securities of Intercell AG may not be offered or sold in the United
States absent registration or an exemption from registration under
the U.S. Securities Act of 1933, as amended. It is not intended to
register any securities of Intercell AG in the United States or to
conduct a public offering in the United States, Austria, Germany or
any other jurisdiction.

end of announcement euro adhoc 30.08.2007 16:27:51
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Intercell AG
Mag. Dott. Astrid Meinl
Corporate Communications
Tel. +43 1 20620-313
ameinl@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market